Inovio Q3 2026 net loss widens 8% to $49.2 million

By Public Technologies
  • Inovio Pharmaceuticals’ third-quarter 2026 net loss widened 8% year-over-year to $49.2 million, primarily driven by higher noncash warrant fair-value losses.
  • Revenue reached $298,901, while operating expenses fell 7% year-over-year to $19.82 million.
  • VOCERYQ secured FDA accelerated approval for adult RRP October 30, 2026; full commercial launch is expected in first-quarter 2027.
  • November’s public offering raised $80.5 million net; cash resources are expected to support operations into late fourth-quarter 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611101605PR_NEWS_USPR_____PH94434) on November 10, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk